Engineered AAVs Use Glymphatic Flow to Target Human Glia in Preclinical Study

Overview

• A peer‑reviewed study published in Nature Biotechnology in July 2026 reports that engineered AAV5 capsids can preferentially infect human glial progenitor cells in mouse brains.
• Researchers created a library of modified capsids and selected variants in vivo using mice transplanted with human glial progenitors to find vectors that favor astrocytes and oligodendrocytes.
• The team delivered those engineered vectors into the cisterna magna and used a short hypertonic treatment to drive spread through the brain via the glymphatic system and to limit exposure to organs such as the liver.
• The work is preclinical and the authors say next steps include additional safety and dosing studies, manufacturing and immune‑response testing, and AI‑guided capsid design before any human trials.
• The platform builds on research into the brain’s glymphatic fluid pathways and growing evidence that targeting glial cells could treat pediatric lysosomal storage and other white‑matter diseases while lowering systemic toxicity risks.